The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
Discover the details behind the FDA's approval of Daklinza (daclatasvir) for use with sofosbuvir to treat HCV genotype 3 infections.
Continue reading »
Learn about Viekira Pak and its success as a standalone treatment for Hepatitis C.
Continue reading »
Find out about Merck's hepatitis drug that is also being tested for HCV/HIV co-infection, liver cirrhosis and more in a clinical trial program.
Continue reading »
A potential new treatment for Hepatitis C that will shorten treatment time and work on all genotypes is expected in 2018.
Continue reading »
Just as the makers of the next generation of Hepatitis C drugs aim for greater safety and effectiveness, they are also trying to eliminate the virus in a shorter period of time.
Continue reading »
The World Health Organization updated its Essential Medicines List to include five drugs used to treat hepatitis C.
Continue reading »
Learn more about Bristol-Myers Squibb’s drugs that had a 93% cure rate in recent trials for Hepatitis C genotype 1.
Continue reading »
Analysis reveals that waiting for treatment shows greater risk for clinical events and death.
Continue reading »
New daclatasvir/sofosbuvir/ribavirin treatment showing promising trial results.
Continue reading »
Learn more about grazoprevir/elbasvir, Merck's Hepatitis C drug that has been fast-tracked for FDA approval.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
